AstraZeneca (STU:ZEGA) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEGA AstraZeneca PLC STU:ZEGA
84 GF Score
Price €78.00
GF Value €89.33
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca  (STU:ZEGA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.26 8.03 7.09 6.87 7.87

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.61 6.58 7.09 8.41 8.19

STU:ZEGA vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.


STU:ZEGA
84GF Score
AstraZeneca PLC STU:ZEGA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=13.259/140.8000*140.8000
=13.259

Current CPI (Mar. 2026) = 140.8000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201606 5.477 101.000 7.635
201609 5.245 101.500 7.276
201612 6.245 102.200 8.604
201703 5.457 102.700 7.481
201706 5.338 103.500 7.262
201709 5.161 104.300 6.967
201712 5.473 105.000 7.339
201803 4.672 105.100 6.259
201806 4.820 105.900 6.408
201809 4.596 106.600 6.071
201812 4.848 107.100 6.373
201903 4.224 107.000 5.558
201906 5.043 107.900 6.581
201909 4.778 108.400 6.206
201912 4.955 108.500 6.430
202003 4.243 108.600 5.501
202006 4.634 108.800 5.997
202009 4.426 109.200 5.707
202012 4.868 109.400 6.265
202103 4.684 109.700 6.012
202106 5.043 111.400 6.374
202109 11.123 112.400 13.933
202112 11.149 114.700 13.686
202203 10.555 116.500 12.757
202206 11.107 120.500 12.978
202209 11.591 122.300 13.344
202212 11.202 125.300 12.588
202303 10.634 126.800 11.808
202306 11.064 129.400 12.039
202309 11.341 130.100 12.274
202312 11.436 130.500 12.339
202403 11.200 131.600 11.983
202406 11.916 133.000 12.615
202409 11.792 133.500 12.437
202412 12.731 135.100 13.268
202503 12.282 136.100 12.706
202506 12.313 138.400 12.527
202509 12.619 138.900 12.792
202512 13.375 139.900 13.461
202603 13.259 140.800 13.259

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €78.00 is trading 12.7% below its estimated GF Value™ of €89.33.

Key valuation signals for STU:ZEGA:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €89.33 vs. price of €78.00 (12.7% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
84GF Score

Get the complete analysis for STU:ZEGA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€89.33
GF Value